Escherichia Coli Infections
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
MSDIreland - Ballydine
1 programColonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing OrganismsN/A
Sharp TherapeuticsPA - Pittsburgh
1 programColonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing OrganismsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsLevofloxacin
Allergy TherapeuticsLevofloxacin
Sharp TherapeuticsColonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
Clinical Trials (3)
Total enrollment: 216 patients across 3 trials
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
Start: Jan 2015Est. completion: Mar 2022111 patients
Phase 2Completed
Enteroaggregative E.Coli (EAEC)
Start: Feb 2008Est. completion: Dec 20085 patients
Phase 1Terminated
NCT01324726Sharp TherapeuticsColonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
Start: Jul 2012Est. completion: Apr 2015100 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.